What is Adimab?
Founded in 2007, Adimab has established itself as a cornerstone of the modern biopharmaceutical ecosystem. The company specializes in a sophisticated yeast-based platform that streamlines the discovery, engineering, and optimization of multispecific antibody therapeutics. By providing a flexible collaboration model, Adimab enables its partners to bypass traditional bottlenecks in drug development, significantly reducing the time-to-market for novel treatments.
The firm's market position is defined by its dual focus on technical excellence and strategic partnership. Unlike traditional contract research organizations, Adimab integrates deeply with its clients, offering a comprehensive suite of services that span the entire antibody development lifecycle. This approach has made it an indispensable asset for companies seeking to improve patient outcomes through precision medicine and advanced biological engineering.
How much funding has Adimab raised?
Adimab has raised a total of $32M across 4 funding rounds:
Series A
$6M
Series D
$8.2M
Series E
$4M
Series F
$13.8M
Series A (2007): $6M with participation from SV Health Investors and Polaris Partners
Series D (2010): $8.2M led by OrbiMed, Google Ventures, SV Life Sciences, Borealis Ventures, and Polaris Partners
Series E (2010): $4M, investors not publicly disclosed
Series F (2012): $13.8M featuring Polaris Partners, Google Ventures, and SV Life Sciences
Key Investors in Adimab
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing coaching, advice, and resources for growth.
Google Ventures
GV is a venture capital firm that invests across multiple stages and sectors, with a strong focus on life sciences, enterprise solutions, and frontier technology innovations.
What's next for Adimab?
Looking ahead, Adimab is well-positioned to capitalize on the increasing demand for complex, multispecific antibody therapeutics. The recent influx of capital will likely be directed toward expanding its engineering infrastructure and deepening its research capabilities in emerging therapeutic modalities. As the biopharma industry shifts toward more targeted, high-efficacy treatments, Adimab's platform remains a vital engine for innovation.
Strategic priorities will likely include the scaling of its internal discovery programs and the further diversification of its partnership portfolio. By maintaining its commitment to scientific rigor and operational flexibility, Adimab is poised to sustain its growth trajectory, reinforcing its status as a leader in the antibody engineering space while continuing to drive value for its stakeholders and the broader healthcare community.
